サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：前立腺肥大症治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
市場調査レポート
商品コード
1342840

前立腺肥大症治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測

Global Benign Prostatic Hyperplasia Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 144 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
前立腺肥大症治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
出版日: 2023年08月01日
発行: Value Market Research
ページ情報: 英文 144 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

前立腺肥大症治療市場の世界需要は、2022年の103億4,000万米ドルから2030年には219億8,000万米ドル近くの市場規模に達すると推定され、調査期間2023年～2030年のCAGRは8.74%です。

前立腺肥大症は、前立腺内部の非がん性細胞増殖です。まず前立腺の内部が冒されます。前立腺肥大の結果、尿道が徐々に圧迫されます。前立腺肥大症の治療には、前立腺肥大症治療薬、手術、低侵襲手術などがあります。これらの処置は、前立腺の異常な成長を抑えたり、膀胱の平滑筋を弛緩させたりするのに役立ちます。

市場力学：

前立腺肥大症の罹患率の高さ、低侵襲手術への嗜好の高まり、革新的な治療法開発のための助成金、投資、資金調達の増加などが主な促進要因です。さらに、前立腺肥大症の罹患率は高齢化、特に高齢男性層の影響を大きく受けており、これが世界の医薬品需要の原動力となっています。また、前立腺肥大症前立腺治療市場は、肥満や運動不足の増加、前立腺肥大症治療薬の存在に対する認知度の向上からも恩恵を受けると予想されます。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を対象としています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは前立腺肥大症治療の世界市場における各セグメントを包括的に評価することもできます。前立腺肥大症治療産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析：

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおける前立腺肥大症治療市場の現在および将来の需要を強調する地域展望をカバーします。さらに、本レポートは、すべての著名な地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 前立腺肥大症治療- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 COVID-19発生の影響分析

第6章 前立腺肥大症治療の世界市場分析：治療別

  • 治療別の概要
  • 実績データと予測データ
  • 治療別分析
  • 薬剤クラス別（α遮断薬、5α還元酵素阻害薬（5-ARI）、ホスホジエステラーゼ-5酵素阻害薬、その他）
  • 低侵襲手術（経尿道的前立腺切除術（TURP）、経尿道的前立腺切開術（TUIP）、ロボット手術、経尿道的マイクロ波温熱療法（TUMT）、前立腺尿道リフト、その他）
  • レーザー治療
  • その他

第7章 世界の前立腺肥大症治療市場分析：エンドユーザー別

  • エンドユーザー別概要
  • 実績データと予測データ
  • エンドユーザー別分析
  • 病院
  • 外来手術センター
  • 専門クリニック
  • その他

第8章 前立腺肥大症治療の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第9章 前立腺肥大症治療企業の競合情勢

  • 前立腺肥大症治療市場競争
  • 提携/協力/合意
  • 合併・買収
  • 新製品の発売
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Boston Scientific Corporation
  • Teleflex Incorporated
  • Endo International Plc
  • Urologix LLC
  • LISA Laser
  • Olympus Corporation
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Treatment (USD MN)
  • Drug Class (Alpha-blockers, 5-Alpha-reductase Inhibitor (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitor, Others) Market Sales by Geography (USD MN)
  • Minimally Invasive Surgeries (Transurethral Resection of the Prostate (TURP), Transurethral Incision of the Prostate (TUIP), Robotic Surgeries, Transurethral Microwave Thermotherapy (TUMT), Prostatic Urethral Lift, Others) Market Sales by Geography (USD MN)
  • Laser Therapy Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by End-user (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Ambulatory Surgical Centers Market Sales by Geography (USD MN)
  • Specialty Clinics Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Benign Prostatic Hyperplasia Treatment Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Benign Prostatic Hyperplasia Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Benign Prostatic Hyperplasia Treatment Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Treatment
  • Market Attractiveness Analysis by End-user
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Treatment (USD MN)
  • Drug Class (Alpha-blockers, 5-Alpha-reductase Inhibitor (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitor, Others) Market Sales by Geography (USD MN)
  • Minimally Invasive Surgeries (Transurethral Resection of the Prostate (TURP), Transurethral Incision of the Prostate (TUIP), Robotic Surgeries, Transurethral Microwave Thermotherapy (TUMT), Prostatic Urethral Lift, Others) Market Sales by Geography (USD MN)
  • Laser Therapy Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by End-user (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Ambulatory Surgical Centers Market Sales by Geography (USD MN)
  • Specialty Clinics Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11219538

The global demand for Benign Prostatic Hyperplasia Treatment Market is presumed to reach the market size of nearly USD 21.98 BN by 2030 from USD 10.34 BN in 2022 with a CAGR of 8.74% under the study period 2023 - 2030.

BPH stands for benign prostatic hyperplasia, which is a noncancerous cell proliferation inside the prostate gland. The inside of the prostate is first affected. The urethra then gradually becomes compressed as a result of prostatic enlargement. BPH medicines, surgery, and minimally invasive surgery are among viable medical treatments for BPH. These procedures aid in reducing the aberrant prostrate growth or relaxing the smooth bladder muscles.

MARKET DYNAMICS:

The main drivers of advancement are the high incidence of BPH, rising preference for minimally invasive procedures, and rising grants, investments, and funding for the development of innovative treatments. Furthermore, the incidence of BPH is greatly influenced by the ageing population, especially the senior male segment, which drives the demand for pharmaceuticals worldwide. The market for benign prostatic hyperplasia prostate treatment is also anticipated to benefit from the rise in obesity, physical inactivity, and increased awareness of the existence of drugs for treating benign prostatic hyperplasia.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of benign prostatic hyperplasia treatment. The growth and trends of benign prostatic hyperplasia treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the benign prostatic hyperplasia treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

  • Drug Class (Alpha-Blockers, 5-Alpha-Reductase Inhibitor (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitor, Others)
  • Minimally Invasive Surgeries (Transurethral Resection Of The Prostate (TURP), Transurethral Incision Of The Prostate (TUIP), Robotic Surgeries, Transurethral Microwave Thermotherapy (TUMT), Prostatic Urethral Lift, Others)
  • Laser Therapy
  • Others

By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Benign Prostatic Hyperplasia Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the benign prostatic hyperplasia treatment market include Boston Scientific Corporation, Teleflex Incorporated, Endo International Plc, Urologix LLC, LISA Laser, Olympus Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . BENIGN PROSTATIC HYPERPLASIA TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment
    • 3.7.2 Market Attractiveness Analysis By End-user
    • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET ANALYSIS BY TREATMENT

  • 6.1 Overview by Treatment
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Treatment
  • 6.4 Drug Class (Alpha-blockers, 5-Alpha-reductase Inhibitor (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitor, Others) Historic and Forecast Sales by Regions
  • 6.5 Minimally Invasive Surgeries (Transurethral Resection of the Prostate (TURP), Transurethral Incision of the Prostate (TUIP), Robotic Surgeries, Transurethral Microwave Thermotherapy (TUMT), Prostatic Urethral Lift, Others) Historic and Forecast Sales by Regions
  • 6.6 Laser Therapy Historic and Forecast Sales by Regions
  • 6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET ANALYSIS BY END-USER

  • 7.1 Overview by End-user
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by End-user
  • 7.4 Hospitals Historic and Forecast Sales by Regions
  • 7.5 Ambulatory Surgical Centers Historic and Forecast Sales by Regions
  • 7.6 Specialty Clinics Historic and Forecast Sales by Regions
  • 7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE BENIGN PROSTATIC HYPERPLASIA TREATMENT COMPANIES

  • 9.1. Benign Prostatic Hyperplasia Treatment Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF BENIGN PROSTATIC HYPERPLASIA TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Boston Scientific Corporation
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Teleflex Incorporated
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Endo International Plc
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Urologix LLC
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. LISA Laser
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Olympus Corporation
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies